Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0035412 (
rhabdomyosarcoma
)
6,156
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
VGLL proteins are transcriptional co-factors that bind TEAD family transcription factors to regulate events ranging from wing development in fly, to muscle fibre composition and immune function in mice. Here, we characterise
Vgll3
in skeletal muscle. We found that mouse
Vgll3
was expressed at low levels in healthy muscle but that its levels increased during hypertrophy or regeneration; in humans,
VGLL3
was highly expressed in tissues from patients with various muscle diseases, such as in dystrophic muscle and alveolar
rhabdomyosarcoma
. Interaction proteomics revealed that VGLL3 bound TEAD1,
TEAD3
and TEAD4 in myoblasts and/or myotubes. However, there was no interaction with proteins from major regulatory systems such as the Hippo kinase cascade, unlike what is found for the TEAD co-factors YAP (encoded by
YAP1
) and TAZ (encoded by
WWTR1
).
Vgll3
overexpression reduced the activity of the Hippo negative-feedback loop, affecting expression of muscle-regulating genes including
Myf5
,
Pitx2
and
Pitx3
, and genes encoding certain Wnts and IGFBPs. VGLL3 mainly repressed gene expression, regulating similar genes to those regulated by YAP and TAZ. siRNA-mediated
Vgll3
knockdown suppressed myoblast proliferation, whereas
Vgll3
overexpression strongly promoted myogenic differentiation. However, skeletal muscle was overtly normal in
Vgll3
-null mice, presumably due to feedback signalling and/or redundancy. This work identifies VGLL3 as a transcriptional co-factor operating with the Hippo signal transduction network to control myogenesis.
...
PMID:VGLL3 operates via TEAD1, TEAD3 and TEAD4 to influence myogenesis in skeletal muscle. 3113 78